BCR and B-cell chronic lymphocytic leukemia: Moreover, as a result of the ability of kinase inhibitors to inactivate enzymes in the BCR signaling pathway, which are aberrantly activated in CLL, leukemic B cells lose not only their ability to proliferate and survive but also to interact with the protective bone marrow microenvironment, a necessary condition to aim the eradication of the disease.